Innate repair receptor peptide (EPO-derived)
ARA-290
Non-erythropoietic EPO-derived peptide that selectively engages the innate repair (EPOR/CD131) in inflammatory and neuropathic models.
Primary Mechanism of Action
Clinical / Scientific
ARA-290 (cibinetide) was engineered from erythropoietin to activate tissue-protective EPOR–β-common-chain (CD131) complexes without stimulating red-cell production. Downstream effects in models include reduced inflammatory cytokines and small-fibre neuropathy readouts.
Pathway Targets
Innate repair receptor (EPOR/CD131)
Scientific explanation
Selective agonism without classical erythropoiesis.
Inflammatory signalling
Scientific explanation
Downstream reduction of selected cytokines in models.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Innate repair receptor (EPOR/CD131) → Inflammatory signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| EPOR/CD131 | Agonism | Tissue-protective signalling | Investigational |
In Plain Language
ARA-290 is a lab-designed sliver of the erythropoietin idea that aims at repair-and- receptors, not at making more red blood cells.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Inflammatory signalling
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.